At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Impact of Tirzepatide on Gastric Emptying (GE) in Overweight/Obese Non-diabetic Subjects and in Overweight/Obese Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating Tirzepatide and Acetaminophen for Overweight and 2 related conditions. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes. The study will last about 13 weeks for each participant, including screening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOverweight, Obesity, Diabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartSep 2020
Primary CompletionJan 2021
TodayJul 2026
First PostedMay 29, 2020
Enrollment StartSep 15, 2020
Primary CompletionJan 7, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.1 years ago
Interventions
Tirzepatidedrug
Tirzepatide administered SC.
Acetaminophendrug
Acetaminophen administered orally.